Here are five things to know:
1. The study was designed to verify and validate Rejuve’s final design for large animals — a sheep in this case. The sheep received fluoroscopic image-guided injections of Rejuve into two lumbar intervertebral discs and had two posterolateral injections per treated level.
2. So far, none of the sheep have experienced infections, clinically relevant or chronic inflammation, or behavioral or neuromuscular effects from the treatment.
3. The study authors concluded the injection is safe and can be effectively administered with fluoroscopic techniques.
4. Rejuve is designed to immediately strengthen and stabilize the disc to reduce pain and eliminate future back pain episodes.
5. More than 80 percent of adults in the United States experience back pain at some point in their lives. Rejuve is designed as a simpler and less expensive treatment than stem cell treatments.
More articles on spine surgery:
Is SSI more common in the summer? 5 things to know about spine surgery
Do neurosurgery residents on cases impact patient outcomes? 5 key notes
How spine surgeons fit into population health—3 key ways practices are changing
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
